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mean fall-related hospital reimbursement of $14,769. LTCF costs
were estimated from RUG classiﬁcations and associated payment
rates. Total reimbursement per resident per year (PRPY) was
calculated as the sum of annualized LTCF and hospital reimburse-
ment. Fall-related costswere estimated as the difference in changes
in reimbursement between groups from pre- to post-periods.
RESULTS: The matched sample included 1130 fallers and 1130
non-fallers. Fallers had substantially more fractures and hospital-
izations in the post-period than non-fallers. The sum of LTCF and
hospital costs increased $4722 PRPY for fallers from pre- to
post-periods; non-fallers’ costs decreased by $1,537 PRPY. The
difference in changes—$6,259 (95% CI = $2,034 to $10,484)
PRPY—represents fall-related costs. About 60% of the difference
was attributable to higher hospitalization costs for fallers. In,
addition fallers weremore likely to be discharged to hospitals or to
die. CONCLUSION: Falls in LTCFs result in substantial costs,
primarily due to higher rates of fractures and hospitalizations.
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OBJECTIVES: To estimate the proportion of patients who
receive pharmacologic treatment for osteoporosis following an
osteoporotic fracture and to identify factors that determine
which patients receive treatment. METHODS: Data were taken
from the Medical Expenditures Panel Survey (MEPS) for 2001–
2003. Women who reported a wrist, vertebral, or hip fracture
after the age of 50 years were identiﬁed. Prescription data were
assessed for these subjects and two groups were identiﬁed: those
who received pharmacologic treatment following a fracture and
those who did not. Using Andersen’s Behavioral Model of Health
Services Utilization, two categories of variables were examined
to determine factors related to treatment: characteristics of the
health delivery system and characteristics of the population at
risk. RESULTS: The ﬁnal sample consisted of 129 subjects. This
represented an estimated 1,238,086 women with a history of
osteoporotic fracture during 2001 to 2003 in the civilian, female,
non-institutionalized U.S. population. Of these, 38% received
treatment. Those treated were most likely to receive either
hormone therapy or bisphosphonates. The only variable that was
signiﬁcantly different (p < 0.05) between those treated and not
treated was type of insurance coverage; patients covered by a
private HMO were more likely to receive pharmacologic treat-
ment. CONCLUSION: Most women do not receive pharmaco-
logic treatment for osteoporosis following a fracture. Substantial
efforts should be made to close the gap between guideline rec-
ommendations and clinical practice. We were unable to identify
variables other than insurance coverage that were related to
treatment.
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OBJECTIVES: Determination of medication persistence, using
administrative pharmacy data, relies on the pharmacist-reported
days supply and an allowable gap between prescriptions. This
concept is used consistently in secondary research, but there are no
standards on the appropriate gap to allow between the run-out of
the days supply of one prescription and the dispensed date of the
patient’s subsequent prescription. The purpose of this research is
to evaluate the impact of varying the allowable gapwhen assessing
persistence in a market with variable dosing frequencies.
METHODS: The osteoporosis market includes competing bis-
phosphonate products with different dosing regimens—weekly or
monthly doses.We assessed the impact of expanding the allowable
gap on persistence and evaluated the impact of allowing different
gaps for each product because differences in dosing frequencies
may impact patients’ reﬁll patterns. Finally, we examined the reﬁll
patterns of patients on each product and the potential impact of
those patterns on the determination of persistence. Cox propor-
tional hazards models, adjusted for patient characteristics, were
used to compare persistence between products. We used the IMS
Longitudinal Prescription (LRx) database, consisting of anony-
mized patient retail prescription records in the U.S. The study
cohort included 165,955 women aged 50 years or older who
initiated therapy between September and November 2005.
RESULTS:As the allowable gap increased, the average persistence
of newly treated bisphosphonate patients also increased (112 days
using 30-day gap, 125 days using 45-day gap), but relative differ-
ences between products were similar, with monthly patients less
persistent than weekly (HR = 1.09 95%CI = (1.08,1.10) using
30-day gap; HR = 1.05 95%CI = (1.03,1.06) using 45-day gap).
When the gap was allowed to differ across products (45-day gap
for monthly vs. 30-day gap for weekly), a different relationship
between products was found (HR = 0.97 95%CI = (0.96,0.98))
CONCLUSION: It is important to consider the allowable gap, in
relation to dosing frequencies, when interpreting results from
persistence measures.
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OBJECTIVES: To compare SF-6D and EQ-5D in both, absolute
values and sensitivity to change over time, in osteoporotic hip
fracture patients in Poland. METHODS: Data were extracted
from prospective study on outcomes of osteoporotic hip fractures
in Poland (PolHipQol study). Eligible patients had to be 60 years
or more, have low energy femoral neck fracture or pertrochant-
eric fracture of the femur, absence of severe cognitive dysfunction
(measured by Hodkinson’s Abbreviated Mental Test Score) and
both SF-36 and EQ-5D post fracture measurements avaiable.
SF-36 scores were translated into SF-6D utilities using the algo-
rithm developed by Brazier et al. The EQ-5D utilities were based
on the European VAS value set. The correlations between pref-
erence measures were assessed using Spearman’s rank correlation
coefﬁcient. Sensitivity to change over one year was evaluated
with the standardized response mean (SRM). RESULTS: Post
fracture data of 65 patients (mean age 77.8; 54 women) and one
year follow-up data of 51 patients were avaiable (9 patients were
ceased and 5 lost to follow-up). Mean SF-6D utility decreased
from 0.65 (SD 0.13) before fracture (recall method) to 0.49
(0.10) after fracture, and then increased to 0.55 (0.12) at the ﬁnal
follow-up. Mean EQ-5D utility decreased from 0.73 (0.22)
before fracture to 0.24 (0.17) after fracture, and then increased
to 0.47 (0.23) at the ﬁnal follow-up. SF-6D and EQ-5D utilities
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